Iconic Labs, Oilex and Alan Green on Catenae Innovation, Destiny Pharma & Stagecoach
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Iconic Labs, Oilex and Alan Green on Catenae Innovation, Destiny Pharma & Stagecoach
Liam Harrington, Chief Business Officer of Iconic Labs #ICON discusses the management contract with JOE Media Ireland and ambition for the company.
Iconic Labs is a multi-divisional new media and technology business positioned to deliver best-in-class consultancy, products, marketing and distribution. It is a consumer-first business that utilises data & insights to exploit new trends and develop disruptive technologies with a focus on future generations. Our current focus is to expand our content platform, suite of digital brands, and technology products both organically and through acquisitions.
Joe Salomon, Managing Director of Oilex #OEX provides an update on their West Kampar interest in Indonesia and also their Indian Cambay gas field.
Oilex’s strategy is to use its extensive technical and commercial expertise to explore, appraise and develop petroleum resources around the Indian Ocean Rim to meet growing energy demands in the region. (Interview starts at 16 minutes 29 seconds)
Alan Green CEO of Brand Communications talks about:
(Interview starts at 26 minutes 3 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.